Hemodialysis Vascular Grafts Market (2024 - 2030)

Hemodialysis Vascular Grafts Market Trends

The global hemodialysis vascular grafts market size was estimated at USD 209.45 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2030. The rising prevalence of chronic kidney disease (CKD) and the need for hemodialysis as a treatment option is one of the major factors boosting the market growth.CKD is a progressive condition in which the kidneys gradually lose function over time.

CKD can be caused by a variety of underlying conditions, including diabetes, hypertension, and glomerulonephritis. Also, the increasing number of people suffering from end-stage renal disease is adding fuel to the market growth. As per the United States Renal Data System (USRDS), nearly 786,000 people in the U.S. are living with End-stage Kidney Disease (ESKD), also known as an ESRD, as of 2021, and this number is anticipated to reach 886,000 by 2030.

Further, the rising geriatric population is a significant driver for the market growth. As per the World Health Organization, approximately 1 in 6 people will be aged 60 years or over across the globe, and by 2050, the world’s population of people aged 60 years and above will be around 2.1 billion. As people age, the risk of developing kidney disease also increases due to numerous factors such as hypertension, diabetes, and cardiovascular disease. The prevalence of kidney disease increases with age and a majority of people with ESRD globally are over the age of 60. According to CDC, in 2021, around 38.0% of the people aged 65 and above suffered from chronic kidney disease in the United States.

Technological advancements in hemodialysis vascular grafts, such as the development of biocompatible materials & improved designs, and increased durability & effectiveness of the devices, are expected to propel the market demand. One of the main technological advancements in the field is the use of biocompatible materials. These materials are designed to be compatible with the body, reducing the risk of rejection and infection. Biocompatible materials such as PTFE and expanded Polytetrafluoroethylene (ePTFE) have been used to create hemodialysis vascular grafts that are more durable and have a longer lifespan than traditional grafts.

The outbreak of COVID-19 had a significant impact on the market. The disrupted supply chains during the pandemic caused delays in the production and distribution of the grafts. In addition, elective surgeries, including those for hemodialysis vascular grafts, were put on hold in many countries, leading to a decline in revenue for the market players. However, the pandemic also increased the number of patients with CKD, as COVID-19 led to acute kidney injury and an increase in preexisting kidney conditions. This is expected to raise demand for hemodialysis vascular grafts in the long term.

Market Concentration & Characteristics

The global market is experiencing growth through innovation, consistently presenting a flow of novel ideas and advanced methodologies. Growing healthcare expenditure has prompted government and private entities to intensify their investments in treating chronic diseases like CKD and ESRD. This augmented financial commitment has resulted in the innovation of advanced and efficacious hemodialysis vascular grafts, strengthening their adoption and market expansion.

Moreover, market players, such as W. L. Gore & Associates, Inc.; C. R. Bard, Inc.; Vascudyne, Inc.; LeMaitre; Getinge AB; VASCULAR GENESIS; InnAVasc Medical, Inc.; CryoLife, Inc.; Merit Medical Systems are involved in merger and acquisition activities. Through M&A activity, these companies can expand their geographic reach and enter new territories.

In addition, companies in hemodialysis vascular grafts invest substantial resources in clinical trials and regulatory submissions to obtain regulatory approval for pipeline products. This may increase the cost of developing novel hemodialysis vascular graft technologies.

The expansion of healthcare spending, progress in technology, and enhanced accessibility to healthcare services in developing nations are key factors propelling market growth. The evolution of design and materials employed in hemodialysis vascular grafts positively impacts patient outcomes, consequently driving heightened demand for these products. Moreover, governmental efforts to enhance healthcare accessibility and promote awareness regarding kidney disease and available treatment options further fuel the market's growth.

Raw Material Insights

Based on raw material, the polytetrafluoroethylene (PTFE) segment held the largest share of 45.50% in 2023. The polytetrafluoroethylene (PTFE) hemodialysis vascular grafts have better pliability & adhesion as compared to other materials and similar patency compared to other synthetic products. PTFE hemodialysis vascular grafts are synthetic tubes made of PTFE material used in hemodialysis to provide patients with kidney failure access to blood.

The segment is witnessing growth owing to rising prevalence of kidney failure, technological advancements in the design, and supportive government and reimbursement policies for hemodialysis procedures, including PTFE hemodialysis vascular grafts.

Furthermore, the segment is anticipated to grow at the fastest CAGR during the forecast period owing to rising funding and investments for kidney diseases, and growing private sector investments in dialysis infrastructure. For instance, In August 2022, Xeltis, a Dutch medical technology company, received USD 16.0 million in investment from Grand Pharma, a Chinese firm. The startup focuses on developing devices for treating cardiovascular diseases and reducing the occurrence of CKD. The investment from Grand Pharmaceutical Group Ltd. consists of equity and a product license, marking the company's first commercial agreement and first funding from an Asian company.

Regional Insights

In 2023, North America dominated the market with a share of 40.03%. The increasing number of patients with non-communicable diseases, such as diabetes and hypertension, which lead to CKDs, is expected to promote the demand for hematology vascular access grafts in this region. Also, the incidence of renal diseases that lead to kidney failure is increasing in North America. Furthermore, the presence of well-defined regulatory guidelines and increase in adoption of biological grafts are some of the factors driving the market in this region.

In addition, surges in healthcare expenditure, advancements in healthcare infrastructure, high disposable income, and an increase in the number of dialysis centers positively affect the market demand.

Market growth in Asia Pacific is anticipated to witness the fastest CAGR over the forecast period. The region has significant unmet needs for patients with ESRD and CKD, owing to factors such as organ donation regulations, choice of organ donor, and high cost of the treatment. Due to these factors, the number of patients undergoing hemodialysis procedures is increasing. Thus, rise in the number of patients undergoing dialysis is expected to boost demand for hemodialysis vascular grafts in Asia Pacific.

Key Companies & Market Share Insights

Some of the key players operating in the market include W. L. Gore & Associates, Inc.; C. R. Bard, Inc.; Vascudyne, Inc.; LeMaitre; Getinge AB; VASCULAR GENESIS; InnAVasc Medical, Inc.; CryoLife, Inc.; Merit Medical Systems are.

• In May 2022, Medtronic announced that it partnered with DaVita to improve patient outcomes and accelerate innovation in kidney care devices. The companies announced the formation of a new, separate medical device company, which will be focused on kidney care to improve overall outcomes in the field of hemodialysis and patient treatment experience.

Hemodialysis Vascular Grafts Market